Diabetes, Gonarthrosis
Conditions
Keywords
SCUBE-1
Brief summary
One consequence of tissue damage caused by tourniquet is ischemia-reperfusion injury. Short-term ischemia leads to vasodilatation and reactive hyperemia resulting in post-ischemic reperfusion microcirculation failure and tissue edema that extends from 30 minutes to 4 hours. SCUBE-1 is a newly defined cell surface molecule. It emerges from many developing cells, including endothelium and platelets. Immunohistochemical demonstration of subendothelial matrix deposition in atherosclerosis in humans. We did not find any study that showed the post-ischemic regression of scube 1, which was shown to be significantly higher in ischemic events in the literature. in this study is aimed to investigate the location / sensitivity of SCUBE-1 in diabetics and nondiabetics after application of regional anesthesia for ischemia-reperfusion injury induced by tourniquet application in knee prosthesis attempts in our aimed patients and compare this with other total antioxidant status (TAS) and MDA of ischemia-reperfusion parameters
Detailed description
After being taken to the operation room, the patient will be divided into two groups as group D (diabetic) and group K (control) by standardized anesthesia monitoring with 5-lead electrocardiogram (ECG), peripheral oxygen saturation (SpO2) and noninvasive blood pressure measurements. In both groups, spinal anesthesia will be applied in a lateral decubitus position using a 22 gauge Quincke spinal needle from the interspinal space as 0.5% heavy marcaine 10-12.5 mg 1 min. Atropine 0.5 mg and ephedrine 5 mg should be administered if bradycardia develops in both groups. The disease tourniquet will be applied after induction, in accordance with the literature, to be above 150 mmHg of the systolic blood pressure.
Interventions
DIAGNOSTIC_TESTspinal anesthesia
before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
Sponsors
Diskapi Yildirim Beyazit Education and Research Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Diabetes mellitus * knee replacement surgery * using a pneumatic tourniquet
Exclusion criteria
* coronary artery disease * renal disorders * cognitive disorders * bleeding diathesis * who have passed general anesthesia * anti-inflammatory drugs treatment * abnormal HbA1c values
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SCUBE-1 | before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation | mean level of SCUBE-1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| malondialdehyde (MDA) | before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation | mean level of MDA |
| total antioxidant capacity | before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation | mean level of total antioxidant capacity (TAC) |
Countries
Turkey (Türkiye)
Outcome results
None listed